Porcine circovirus type 3 antigen detection reagent strip as well as preparation method and application thereof

By cloning the PCV3 Cap gene and preparing corresponding antibodies, a pig cyclovirus type 3 antigen detection reagent strip was developed, which solved the problem of PCV3 detection in the existing technology, achieved rapid and sensitive virus detection, and supported the Effective monitoring and risk assessment of PCV3 virus.

CN119019544AActive Publication Date: 2024-11-26ZHEJIANG SCI-TECH UNIV +1
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411090226.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-09
Publication Date
2024-11-26
Estimated Expiration
2044-08-09

AI Technical Summary

Technical Problem

The lack of fast and convenient antigen detection methods for pig circovirus type 3 (PCV3) in the prior art, which makes the diagnosis take a long time and high cost, making it difficult to meet the clinical needs of pig farms, and there is no safe and effective PCV3 vaccine product available.

Method used

By cloning the PCV3 Cap gene, recombinant prokaryotic expression vectors were constructed, recombinant PCV3 Cap protein was obtained, and monoclonal and polyclonal antibodies were prepared, and pig cyclovirus type 3 antigen detection reagent strips were developed, and these antibodies were used for rapid detection on the test strips. .

Benefits of technology

Rapid, sensitive and specific detection of PCV3 virus and PCV3 Cap proteins has been achieved, providing effective diagnostic tools for clinical practice, filling the gaps in the existing technology, and supporting the rapid monitoring and risk assessment of PCV3 virus.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119019544A_ABST
    Figure CN119019544A_ABST
Patent Text Reader

Abstract

The invention discloses an anti-PCV3Cap protein monoclonal antibody, the anti-PCV3Cap protein monoclonal antibody is a monoclonal antibody 1D4-10-16 and a monoclonal antibody 2B6-1-1, and the amino acid sequences of a heavy chain variable region and a light chain variable region of the monoclonal antibody 1D4-10-16 are respectively shown as SEQ ID NO.3 and SEQ ID NO.4. The invention also discloses a preparation method of the anti-PCV3Cap protein monoclonal antibody. The invention also discloses a porcine circovirus type 3 antigen detection test strip, the test strip comprises a detection test strip and a matched sample diluent, the detection test strip comprises a PVC base plate, and a sample pad, a latex microsphere pad, a nitrocellulose membrane and absorbent paper are sequentially fixed on the PVC base plate; the latex microsphere pad is latex microspheres marked with an effective amount of PCV3Cap protein polyclonal antibody; a detection line and a quality control line are marked on the surface of the nitrocellulose membrane, the detection line is an effective amount of monoclonal antibody 1D4-10-16, and the quality control line is an effective amount of PCV3Cap protein. The test strip has good sensitivity and specificity, and a new product is provided for clinical rapid detection of PCV3 infection.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biotechnology, and in particular to a porcine circovirus type 3 antigen detection reagent strip, a preparation method and an application thereof. Background Art

[0002] Porcine circovirus (PCV) is a single-stranded DNA virus (ssDNA) and one of the smallest known self-replicating viruses. So far, four types have been discovered, namely PCV1, PCV2, PCV3 and PCV4.

[0003] At present, the technology of PCV3 isolation and cultivation is not mature, and there is no safe and effective PCV3 vaccine product. The prevention and control of PCV3 still needs to rely on biosafety prevention and control measures. In biosafety prevention and control, pig farms should do a good job of monitoring PCV3, avoid introducing new breeds, eliminate infected pigs in time, and eliminate the source of infection; do a good job of physical isolation to prevent carriers from bringing them into the pig farm; implement disinfection work well to cut off the transmission route, etc.

[0004] At present, the diagnostic technology for emerging animal diseases such as PCV3 is insufficient, mainly based on conventional PCR and qPCR molecular biological detection technology. These detection methods are time-consuming, costly, and require high equipment, which is not convenient for rapid diagnosis and application in pig farms. There are few studies on PCV3 serological detection technology, and only a small number of reports on indirect ELISA using recombinant PCV3 Cap protein. There are currently no rapid detection methods or products for PCV3 antigens on the market.

[0005] Given that there is currently no commercial PCV3 vaccine available, it is urgent to establish corresponding pathogen monitoring and assessment methods, comprehensively carry out systematic monitoring and risk assessment of PCV3, timely grasp the epidemic situation and scientifically analyze trends, and effectively prevent and control the outbreak of such epidemics.

[0006] Based on this, this study cloned the PCV3 Cap gene, connected it to the pET-32a vector to construct a recombinant prokaryotic expression vector, transformed Escherichia coli competent cells, and obtained recombinant PCV3 Cap protein through IPTG induction and nickel column chromatography purification. The purified recombinant PCV3 Cap protein was used as an antigen to immunize New Zealand white rabbits and BALB / c mice to prepare polyclonal antibodies and monoclonal antibodies. Further, the prepared recombinant PCV3 Cap protein, polyclonal and monoclonal antibodies were used as raw materials to develop PCV3 antigen rapid detection reagent strips. The detection of clinical samples confirmed that the rapid detection reagent strips can be used for clinical rapid detection. Summary of the invention

[0007] In order to make up for the deficiencies of the prior art, the object of the present invention is to provide a porcine circovirus type 3 antigen detection reagent strip and a preparation method and application thereof.

[0008] Therefore, on one hand, the present invention discloses an anti-PCV3 Cap protein monoclonal antibody, wherein the anti-PCV3 Cap protein monoclonal antibodies are monoclonal antibody 1D4-10-16 and monoclonal antibody 2B6-1-1, wherein the amino acid sequences of the heavy chain variable region and the light chain variable region of the monoclonal antibody 1D4-10-16 are shown in SEQ ID NO.3 and SEQ ID NO.4, respectively.

[0009] On the other hand, the present invention also discloses a porcine circovirus type 3 antigen detection test strip, which includes a test strip and a matching sample diluent, wherein the test strip includes a PVC base plate, on which a sample pad, a latex microsphere pad, a nitrocellulose membrane and absorbent paper are fixed in sequence; the latex microsphere pad is a latex microsphere marked with an effective amount of PCV3 Cap protein polyclonal antibody; a detection line and a quality control line are drawn on the surface of the nitrocellulose membrane, wherein the detection line is an effective amount of monoclonal antibody 1D4-10-16, and the quality control line is an effective amount of PCV3 Cap protein.

[0010] Preferably, the concentration of the PCV3 Cap protein polyclonal antibody on the latex microsphere pad of the present invention when labeling the latex microspheres is 1 mg / mL.

[0011] Preferably, the PCV3 Cap protein polyclonal antibody of the present invention is a rabbit anti-PCV3 Cap protein polyclonal antibody, and its ELISA titer is 1:80000.

[0012] Preferably, the concentration of the monoclonal antibody 1D4-10-16 on the detection line of the present invention is 1 mg / mL.

[0013] Preferably, the concentration of PCV3 Cap protein on the test line of the present invention is 1 mg / mL.

[0014] Preferably, the amino acid sequence of the PCV3 Cap protein of the present invention is as shown in SEQ ID NO.1.

[0015] Preferably, the nucleotide sequence of the codon-optimized PCV3 Cap protein of the present invention is as shown in SEQ ID NO.2.

[0016] In another aspect, the present invention also discloses a use of the monoclonal antibody 1D4-10-16 in the preparation of a PCV3 or PCV3Cap protein detection reagent.

[0017] The monoclonal antibody 1D4-10-16 and the monoclonal antibody 2B6-1-1 prepared by the present invention have good sensitivity and specificity, and are suitable for the detection of PCV3 and PCV3 Cap protein, such as the detection of antibodies to PCV3 antigen or PCV3 Cap protein by ELISA method, Western blot method, colloidal gold method or chemiluminescence method.

[0018] Meanwhile, the PCV3 Cap protein prepared by the present invention has good immunogenicity and a high expression level; and the PCV3 Cap protein polyclonal antibody prepared by the present invention also has good sensitivity and specificity, and is suitable for the detection of PCV3 and PCV3 Cap protein, such as ELISA method, Western blot method, colloidal gold method or chemiluminescence method to detect antibodies against PCV3 antigen or PCV3 Cap protein.

[0019] The porcine circovirus type 3 antigen detection reagent strip developed by the present invention on the basis of the aforementioned monoclonal antibody 1D4-10-16, monoclonal antibody 2B6-1-1, PCV3 Cap protein and PCV3Cap protein polyclonal antibody has good sensitivity and specificity, is suitable for the rapid detection of PCV3 virus and PCV3 Cap protein, and provides a good product for the rapid detection of PCV3 in clinical practice. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 Schematic diagram of the construction of recombinant plasmid pET-32a-Cap.

[0021] Figure 2 The recombinant plasmid pET32a-Cap was transformed into the expression bacteria Rossatta and the expression was induced by SDS-PAGE identification.

[0022] Figure 3 Purification and identification results of recombinant PCV3 Cap protein inclusion bodies.

[0023] Figure 4 Western Blot (His primary antibody) identification results of recombinant PCV3 Cap protein.

[0024] Figure 5 Western Blot (polyclonal antibody) identification results of recombinant PCV3 Cap protein.

[0025] Figure 6 ELISA titer test results of sera from immune mice.

[0026] Figure 7 Positive monoclonal antibody ELISA titer determination (undiluted).

[0027] Figure 8SDS-PAGE electrophoresis results of the purified 1D4-10-16 monoclonal antibody.

[0028] Fig. 9 Identification of recombinant PCV3 Cap protein by Western Blot (1D4-10-16 monoclonal antibody).

[0029] Fig.10 Results of ascites titer determination of 1D4-10-16 and 2B6-1-1 monoclonal antibodies.

[0030] Fig.11 Specificity identification results of 1D4-10-16 and 2B6-1-1 monoclonal antibodies.

[0031] Fig.12 Screening results of labeled antibodies and systems.

[0032] Fig.13 Screening results of the labeled antibody corresponding to the membrane antibody.

[0033] Fig.14 Marker antibody sensitivity test results.

[0034] Fig.15 The test results of the test strips prepared with the same antibody as the membrane dot antibody and the labeled antibody.

[0035] Fig.16 Diagram of the best combination of membrane antibodies and labeled antibodies at different spots.

[0036] Fig.17 Product packaging picture.

[0037] Fig.18 Schematic diagram of the test strip assembly. A: sample pad, B: latex microsphere pad, C: test line, D: quality control line.

[0038] Fig.19 Schematic diagram of test strip detection and judgment.

[0039] Fig. 20 Clinical serum sample test results. DETAILED DESCRIPTION

[0040] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art of the present invention. The terms used herein in the specification of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the present invention. The term "and / or" used herein includes any and all combinations of one or more related listed items.

[0041] Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art. Unless otherwise specified, the reagents and materials used in the following examples are commercially available.

[0042] Example 1: Preparation of recombinant PCV3 Cap protein

[0043] 1. Acquisition of target gene and construction of expression vector

[0044] The PCV3 Cap protein sequence was searched in the NCBI database, and the conservative protein sequence was selected by sequence comparison. The amino acid sequence encoding the PCV3 Cap protein is shown in SEQ ID NO.1. The target gene was synthesized after codon optimization in the E. coli expression system (the sequence after codon optimization is shown in SEQ ID NO.2). After double digestion with restriction endonucleases BamHI and HindⅢ, it was connected into the pET32a prokaryotic expression vector to construct a recombinant prokaryotic expression vector. The construction schematic diagram is shown in Figure 1 The recombinant plasmids were transferred into TG1 clone bacteria, and the recombinant vectors obtained after screening and identification were named pET-32a-Cap.

[0045] 2. Expression, purification and identification of target protein

[0046] The recombinant plasmid pET-32a-Cap was transformed into E. coli Rossatta (DE3) expression bacteria, and the recombinant Cap protein was obtained by IPTG induction, purified by His nickel column, and identified by SDS-PAGE electrophoresis and Western Blot (His primary antibody). The specific steps are as follows:

[0047] (1) Protein expression: Inoculate the recombinant expression bacteria into LB medium at a ratio of 1:100, add Amp antibiotics at a final concentration of 1 mM, shake the culture at 37°C, 220 rpm for 3-4 h, then add IPTG at a final concentration of 1 mM for induction, and culture overnight at 16°C, 220 rpm.

[0048] (2) Bacterial cell disruption: Collect the cultured bacterial liquid induced overnight, centrifuge at 4000rpm for 40min to obtain bacterial cells; resuspend and wash with an appropriate amount of sterile PBS solution, centrifuge at 12000rpm, 4℃ for 10min, and discard the supernatant; resuspend the bacterial cells with a small amount of pre-cooled purified washing solution or PBS, and place them in an ultrasonic disruptor for disruption, with the conditions of supersonication for 3s and stop for 3s, and ultrasonication in an ice bath for 20-30min; finally centrifuge at 12000rpm, 4℃ for 15min to collect the supernatant and precipitate respectively. The samples before and after induction, the supernatant and the precipitate were subjected to SDS-PAGE electrophoresis, and the results are as follows: Figure 2 As shown in the figure, PCV3 Cap protein is expressed in the form of inclusion bodies.

[0049] (3) Purification of inclusion body protein: Collect the precipitate after bacterial cell disruption, dissolve the inclusion bodies with inclusion body lysis solution, centrifuge the dissolved inclusion body suspension at 4°C and 12,000 rpm for 15 min, collect the supernatant and dialyze it in 6M, 4M, and 2M urea refolding buffer for 2 h, and then dialyze it in 0M urea refolding dialysate overnight. Collect the dialyzed protein solution and centrifuge it at 4°C and 12,000 rpm for 10 min, separate the dialyzed supernatant and the dialyzed precipitate, collect the dialyzed supernatant and the dialyzed precipitate for SDS-PAGE electrophoresis analysis.

[0050] (4) SDS-PAGE electrophoresis and Western Blot identification: The purified PCV3 Cap was prepared and electrophoresed on 12% SDS-PAGE gel, stained with Coomassie Brilliant Blue, and decolorized. The results are as follows: Figure 3 Western Blot was performed using His antibody, and the results are as follows: Figure 4 .

[0051] The results showed that the target protein was expressed in the E. coli Rossatta (DE3) expression bacteria in the form of inclusion bodies. The recombinant protein was obtained by conventional denaturation and renaturation methods of inclusion body proteins and nickel column chromatography, and was identified as recombinant PCV3 Cap protein by SDS-PAGE and Western blot. Further tests such as purity (SDS-PAGE purity> 90%) and concentration (calculated expression amount after purification can reach 1g / L or above) confirmed that it met the requirements for the preparation of monoclonal and polyclonal antibodies to antigens.

[0052] Example 2: Preparation of anti-PCV3 Cap protein polyclonal antibodies

[0053] 1. Animal immunization and preparation of antiserum: The recombinant PCV3 Cap protein prepared above was quantified using a BCA protein quantification kit and diluted to a concentration of 1 mg / mL. Animal immunization was performed using multiple subcutaneous injections on the back, and immunization was performed on days 0, 10, 20, and 30. For each immunization, the antigen was emulsified with an equal volume of Freund's adjuvant, i.e., 1 mL of adjuvant + 1 mL of antigen (concentration of 1 mg / mL). The total amount of emulsified vaccine for each immunization was 2 mL, of which the antigen content was 1 mg. Freund's complete adjuvant was used for the first immunization, and Freund's incomplete adjuvant was used for the remaining three booster immunizations. Blood was collected from the ear vein of each group of experimental rabbits before immunization on day 0 to separate serum, which was used as negative control serum. Blood was collected from the heart of the experimental rabbits on day 40 of the first immunization, and immune serum was separated.

[0054] 2. Purification of antiserum: After the antiserum to be purified is filtered with a 0.45μm filter membrane to remove impurities, it is placed on a Protein AAgarose gravity column and combined for 30 minutes to allow the IgG in the serum to fully bind to Protein A. Discard the liquid in the column, wash with 10 times the column volume of TBS solution to remove non-specifically bound proteins, and measure the absorbance value of the eluted liquid at 280nm by NanoDrop, and continue washing until no impurities are eluted. After washing, use 10mL 50mmol / L glycine (pH 1.9) solution as an eluent to elute the bound specific antibodies. Collect in separate tubes, and determine which collection tubes the target antibody is eluted in according to the protein concentration. Finally, neutralize the eluted antibody solution with a 1mol / L NaHCO3 solution, add glycerol to a final concentration of 50%, and store at -80℃.

[0055] 3. Determination of polyclonal antibody titer: Purified rabbit anti-PCV3 Cap protein polyclonal antibody is used for indirect ELISA test. When the sample absorbance value / negative serum absorbance value>2.1, it is considered positive. Specific method steps:

[0056] (1) Antigen coating: dilute the antigen to 1 μg / mL with antigen coating buffer, add 100 μL of diluted antigen to each well of the ELISA plate, and incubate at 4°C overnight; (2) Washing: shake off the antigen coating solution, wash 3 times with washing solution, and oscillate on a 96-well plate shaker for 1 min each time; (3) Blocking: add 300 μL of blocking solution to each well, cover the well, and incubate in a 37°C biochemical incubator for 2 h; (4) Washing: remove the blocking solution and wash 3 times in the same way; (5) Incubate with primary antibody: add 100 μL of the test antibody diluted in gradient with antibody diluent to each well, cover the well, and incubate at 37°C for 1 h. The serum collected on day 0 was used as the negative control. (6) Washing: remove the antibody to be tested and wash 4 times; (7) Incubate with secondary antibody: add 100 μL of HRP-labeled goat anti-rabbit secondary antibody (1:1000 dilution) to each well, cover the lid, and incubate at 37°C for 1 hour; (8) Washing: remove the secondary antibody and wash 4 times; (9) Color development: add 200 μL of TMB color development solution to each well and color develop at room temperature in the dark for 15 minutes; (10) Stop color development: add 50 μL of stop solution to each well to stop the color development reaction; (11) Determine the absorbance value: wipe the bottom of the ELISA plate with alcohol cotton to remove stains, put it into the microplate reader, and read the absorbance value at a wavelength of 450 nm. If the OD value of the antibody well to be tested is 450 The value is higher than the OD of the negative control well. 450 If the value is 2.1 times greater, it is considered positive.

[0057] The purified rabbit anti-PCV3 Cap protein polyclonal antibody was subjected to indirect ELISA detection. After calculation, the titer of the rabbit anti-PCV3 Cap protein polyclonal antibody prepared this time was 1:80000. The results are shown in Table 1.

[0058] Table 1 Anti-PCV3 Cap polyclonal antibody titer determination table

[0059]

[0060] The polyclonal antibody prepared as above was further used as primary antibody and the recombinant PCV3 Cap protein as antigen to verify its binding specificity with the antigen protein. The results confirmed that the prepared polyclonal antibody can specifically recognize the recombinant PCV3 Cap protein. The results are shown in Figure 5 shown.

[0061] Example 3: Preparation of monoclonal antibodies against PCV3 Cap protein

[0062] 1. Mouse immunization

[0063] (1) Immunize BALB / c mice with the purified antigen at a dose of 100 μg / mouse for the first immunization and 50 μg / mouse for the second to fourth immunizations. During the immunization process, Freund's adjuvant and antigen were emulsified and mixed at a volume ratio of 1:1. Freund's complete adjuvant was used for the first immunization, while Freund's incomplete adjuvant was used for the subsequent booster immunization stage. (2) Immunization was performed by subcutaneous multi-point injection in mice, ensuring that the interval between each immunization was 2 weeks. Starting from the third immunization, blood samples were collected from the mouse eye sockets on the 7th day after each immunization for the preparation of serum for subsequent evaluation and analysis. (3) On the 7th day after the fourth immunization, blood samples were collected from the mouse eye sockets again. After the blood samples were centrifuged, the supernatant was taken for subsequent analysis.

[0064] 2. Determination of the titer of immune serum and screening of hybridoma cells

[0065] The serum of the above-mentioned immunized mice was tested by indirect ELISA method, and the spleen of mice with higher titers was aseptically removed. B lymphocytes were separated and fused with sp2 / 0 myeloma cells, and screened by HAT medium to obtain hybridoma cell lines that can produce antibodies. The results of ELISA titer test of serum antibodies of immunized mice are shown in Figure 6 shown.

[0066] According to the results of the ELISA test of the above immune mouse serum, the spleen of mouse 13# was finally selected for cell fusion. After fusion, 145 positive hybridoma cell lines were obtained through preliminary screening. The positive hybridoma cell culture supernatant was further screened by indirect ELISA to obtain 20 positive hybridoma cell lines with higher titers for monoclonal amplification. At the same time, 20 hybridoma culture supernatants were taken for ELISA and Western blot verification screening. The results are shown in Figure 7 As shown, two hybridoma cells with high titers (1D4-10-16 and 2B6-1-1) were finally selected and injected intraperitoneally into mice to prepare ascites, and the antibodies in the ascites were affinity purified.

[0067] 3. Preparation, purification and identification of monoclonal antibodies

[0068] The two hybridoma cell lines (1D4-10-16 and 2B6-1-1) were expanded and cultured at 1×10 7 Hybridoma cells / mouse were injected intraperitoneally to prepare ascites. The collected ascites was centrifuged at 4000rpm for 10min, the precipitate was discarded, and the antibody was purified after filtering with a 0.45μm / 0.22μm filter membrane. The purified monoclonal antibody was identified by SDS-PAGE and Western blot. The results are shown in Figure 8 and 9 .

[0069] On the basis of the above identification, the titer of the purified ascites was further tested by ELISA. The results showed that both monoclonal antibodies had high titers, indicating that both monoclonal antibodies had good sensitivity. Fig.10 shown.

[0070] At the same time, Western blot detection was performed on PCV2 Cap protein (prepared by the inventor) using the two monoclonal antibodies prepared by the present invention. The results showed that the two monoclonal antibodies had no specific binding to PCV2 Cap protein, indicating that the two monoclonal antibodies had good specificity. Fig.11 shown.

[0071] Example 4: Determination of variable region sequences of hybridoma monoclonal antibody genes

[0072] Hybridoma cells (1D4-10-16) were lysed to extract total RNA. After qualified detection, RNA was reverse transcribed into cDNA using RACE technology; heavy chain and light chain variable region sequences were obtained by PCR amplification; the target fragment was connected to the vector using ligase, and the ligation product was transformed into Escherichia coli competent cells, and then a single clone was picked for sequencing; finally, the variable region sequence of the monoclonal antibody gene was obtained by analyzing and annotating the sequencing results, as shown in Table 2 and SEQ ID NO.3 and SEQ ID NO.4.

[0073] Table 2 Amino acid sequence information of the variable region of monoclonal antibody 1D4-10-16

[0074]

[0075] The recombinant PCV3 Cap protein was obtained by mouse immunization, spleen lymphocyte isolation, cell fusion and monoclonal cell screening to obtain hybridoma cell lines. The culture supernatant of the hybridoma cell lines was titered and identified by ELISA and Western blot experiments. Finally, two high-titer monoclonal cells (1D4-10-16 and 2B6-1-1) were selected and injected into the mouse peritoneal cavity to prepare ascites. The titer, concentration and subtype of the ascites were detected after affinity purification. The results confirmed that 1D4-10-16 and 2B6-1-1 monoclonal hybridoma cells were injected into the mouse peritoneal cavity to obtain two monoclonal antibodies with a titer greater than 1:1024000. The variable region sequence of the monoclonal antibody gene of the 1D4-10-16 hybridoma cell was further obtained by sequencing, wherein the amino acid sequences of the heavy chain variable region and the light chain variable region are shown in SEQ ID NO.3 and SEQ ID NO.4, respectively.

[0076] Example 5: Preparation of porcine circovirus type 3 antigen detection test strip (latex method)

[0077] 1. Experimental materials: PCV3 Cap monoclonal antibody (2B6-1-1) is recorded as antibody 1, monoclonal antibody (1D4-10-16) is recorded as antibody 2, PCV3 Cap polyclonal antibody is recorded as antibody 3, recombinant PCV3 Cap protein (quality control product), pig and dog serum, NC membrane, BSA blocking solution, Tris-BSA reconstitution solution (high sugar), sample pad (glass cellulose), labeling pad (glass cellulose), etc.

[0078] 2. Experimental methods

[0079] (1) Antibody labeling: Antibody 1, antibody 2, and antibody 3 are labeled according to the following steps.

[0080] ① Cleaning: Take 200 μL of latex, add 800 μL of borax washing solution, centrifuge at 12000rpm for 15min, and discard the supernatant; add 800 μL of borax washing solution, ultrasonically mix (maximum superpower 4%, time 2min), centrifuge at 12000rpm for 15min, and discard the supernatant; add 800 μL of 0.05M MES (pH 5.5) buffer solution, ultrasonically mix (maximum superpower 4%, time 2min).

[0081] ② Activation: Take 800 μL of the solution obtained in the above step (1), mix it by ultrasonication, add 20% of the original latex volume of 10 mg / mL EDAC (freshly prepared and used) to activate for 0.5 h; then add 10% of the original latex volume of 10 mg / mL NHS (freshly prepared and used) to activate for 0.5 h; after activation, divide it into 12 portions, centrifuge at 12000 rpm for 15 min, discard the supernatant, add 4 times the original latex volume of 100 mM borax cleaning solution / 0.05 M MES / 0.05 MPB to each portion and mix it by ultrasonication.

[0082] ③ Labeling: dilute the raw material to 1 mg / mL with 100 mM borax cleaning solution / 0.05 M MES / 0.05 M PB, add to the solution obtained in step (2), mix by ultrasonic, label for 1.5 h, centrifuge at 12000 rpm for 15 min, and discard the supernatant.

[0083] ④ Blocking: Add 800 μL of 1# blocking solution to the precipitate obtained in the previous step, mix by ultrasonication, block for 0.5 h, centrifuge at 12000 rpm for 15 min, and discard the supernatant.

[0084] ⑤Redissolve: Add 1600μL 1# reconstitution solution to the precipitate and mix by ultrasonic.

[0085] ⑥ Gold spraying: spraying volume 1.0, 1.5 and 2.0 μL / cm onto K75 glass cellulose and drying at 45°C overnight.

[0086] (2) Screening of labeled antibodies and systems: The labeled antibodies 1, 2 and 3 were diluted with PB (0.05 M PB solution), MES (0.05 M MES solution) and PS (100 mM borax solution) respectively and then applied to the membrane (concentration 1.0 mg / mL). The recombinant PCV3 Cap protein solution diluted 100 times and 500 times was added to the sample wells as a quality control product. At the same time, Ag3 dedicated buffer (1) was used as a negative control to test and screen the labeled antibodies and diluent system. The test system is shown in Table 3. The test results are shown in Table 3. Fig.12 As shown in the figure, the labeled antibody 2 has bands in the PB, MES and borax solution diluents for the 100-fold and 500-fold diluted quality control products, indicating that antibody 2 can be used as a labeled antibody for the detection test strip.

[0087] Table 3 Labeled antibody and diluent screening system

[0088]

[0089] Note: PB is 0.05 M PB solution, MES is 0.05 M MES solution, and PS is 100 mM borax solution.

[0090] (3) Screening of membrane spot antibodies: Antibodies 1, 2 and 3 labeled by the latex method were used as labeled antibodies, 100-fold and 500-fold diluted recombinant PCV3 Cap proteins were used as quality control, and Buffer (1) and Buffer (2) were used as negative controls to screen the corresponding membrane spot antibodies. The screening system is shown in Table 4. The test results are shown in Table 4. Fig.13 In the figure, X and Y corresponding to monoclonal antibody 1 are antibodies 2 and 3, X and Y corresponding to monoclonal antibody 2 are antibodies 1 and 3, and X and Y corresponding to polyclonal antibody 3 are antibodies 1 and 2. As can be seen from the figure, labeled antibody 2 corresponding to spot membrane antibody 1, labeled antibody 2 corresponding to spot membrane antibody 3, and labeled antibody 3 corresponding to spot membrane antibody 2 have better effects.

[0091] Table 4 Dot membrane antibody screening system

[0092]

[0093] (4) Labeled antibody sensitivity test: The recombinant PCV3 Cap protein was diluted 500, 2500, 10000, 400000 and 160000 times with MES and PS solutions respectively to test the sensitivity of labeled antibody 2, with Buffer (1) as the negative control. The labeled antibody sensitivity test system is shown in Table 5. The test results are shown in Table 5. Fig.14 As can be seen from the figure, the labeled antibody 2 has a corresponding band in the MES solution for the quality control product diluted 10,000 times, and the borax solution has a corresponding band in the quality control product diluted 2,500 times. This shows that the labeled antibody 2 has a higher sensitivity in the MES solution.

[0094] Table 5 Labeled antibody sensitivity test system

[0095]

[0096] (5) Test strips with labeled antibody 2 + spot antibody 2 for serum sample testing: Antibody 2 was used as the spot antibody (1.0 mg / mL) and a test strip was prepared with antibody 2 labeled by latex method. The test was performed using 18 clinical pig sera. The results are shown in Table 1. Fig.15As can be seen from the figure, all serum samples showed bands, indicating that false positive results appeared, indicating that false positive results appeared when the test strip was prepared by combining labeled antibody 2 and dot antibody 2. Similarly, test strips were prepared by combining labeled antibody 1 + dot antibody 1 and labeled multimer 3 + dot antibody 3, respectively, and verified using negative pig serum and dog serum. The results also showed false positive bands, indicating that false positive results appeared when the same antibody was used as dot antibody and labeled antibody to prepare test strips.

[0097] (6) Test strips were prepared by combining different antibodies as labeled antibodies and membrane spot antibodies: Based on the above, in order to screen the best combination of different membrane spot antibodies and labeled antibodies, antibody 1, antibody 2 and antibody 3 were combined in pairs to prepare test strips. The detection effects were tested using three portions of pig sera (S15, S23 and S24), a 500-fold diluted positive quality control (recombinant PCV3 Cap protein) and a negative control (Buffer). The test system is shown in Table 6. The results are shown in Table 6. Fig.16 ,It can be seen from the figure that the combination of antibody 3 and antibody 2 meets the requirements and can be used for the preparation of test strips.

[0098] Table 6 Test system of combined labeled antibody and membrane antibody

[0099]

[0100] (7) Product preparation: According to the test strip process screened above, prepare porcine circovirus type 3 antigen detection test strips, see Fig.17 As shown, the product specification is 10 pieces / box, which is mainly used for rapid screening of PCV3 virus and PCV3 Cap protein in pig serum / plasma, tissue samples and other samples. The developed products provide reagent products for clinical rapid detection of PCV3 infection. The specific process is briefly described as follows:

[0101] ① Preparation of nitrocellulose membrane

[0102] Preparation of coating buffer: Add 1 g of sucrose to 100 mL of PBS (0.01 mol / L, pH 7.2) to prepare coating buffer, filter through a 0.22 μm filter membrane for sterilization, and store at 2-8°C for later use.

[0103] Preparation of nitrocellulose membrane: stick the nitrocellulose membrane to the corresponding position of the PVC bottom plate, dilute antibody 2 (monoclonal antibody 1D4-10-16) to 1 mg / mL with coating buffer, adjust the marking position and height of the film marking machine, and mark the T line, which is the detection line. The T line is close to the end of the latex microsphere pad. Dilute the PCV3 Cap protein to 1 mg / mL with coating buffer, adjust the marking position and height of the film marking machine, and mark the C line, which is the quality control line. The C line is close to the absorption pad, and the distance between the two lines is 5-8 mm. Dry in a 37°C oven for 15 hours, seal in an aluminum foil bag with desiccant, and store at 2-30°C for later use.

[0104] ②Preparation of latex pad

[0105] Labeling: Add antibody 3 (PCV3 Cap polyclonal antibody) to the latex microspheres at a concentration of 1 mg / mL, and rotate and mix for 2 hours. Add BSA to a final concentration of 1%, and rotate and mix for 30 minutes. Centrifuge at 10,000 rpm for 30 minutes at 2-8°C, discard the supernatant, collect the precipitate, and resuspend the precipitate in 1 mL of preservation solution (preparation of preservation solution: weigh 0.25 g Tris, 1 g BSA, and 2 g sucrose and add them to 90 mL of double distilled water to dissolve. After complete dissolution, mix well, adjust the pH to 8.0, and then add double distilled water to make up to 100 mL) and ultrasonicate for 1 minute, and store at 2-8°C.

[0106] Preparation of latex microsphere pad: Spread the resuspended latex microsphere labeled antibody evenly on the treated latex microsphere pad, dry in a 37°C oven for 15 h, seal in an aluminum foil bag, and store at 2-30°C for later use.

[0107] ③ Sample pad processing

[0108] The sample pad (300 mm × 20 mm) was immersed in blocking solution (preparation of blocking solution: weigh 1 g of BSA and add it to 10 mL of purified water to fully dissolve) for 30 min, then dried in an oven at 37°C for 15 h, packaged in an aluminum foil bag, and stored at 2-30°C for later use.

[0109] ④Assembly of test strips

[0110] like Fig.18 As shown, the sample pad, latex microsphere pad, and absorbent pad are sequentially pasted to the corresponding positions of the PVC bottom plate with the nitrocellulose membrane, so that the latex microsphere pad and the absorbent pad are respectively in contact with the nitrocellulose membrane, and the sample pad is in contact with the latex microsphere pad, to form a large plate.

[0111] ⑤Packaging

[0112] Use a strip cutter to cut the large plate into 3mm wide test strips, put them into the outer shell, and seal them in an aluminum foil bag, which contains a test strip, a straw, and a bag of desiccant. Store them at 2-30℃ away from light for future use. The shelf life is 24 months.

[0113] ⑥ Preparation of sample buffer

[0114] 1×PBS (0.01mol / L PBS pH 7.4) was sterilized by filtration through a 0.22μm microporous filter membrane. Aseptically aliquoted, 10mL / tube, and stored at 2-30℃ for later use.

[0115] ⑦Assembly and inspection of test strips: Assemble the test strip components that have passed the inspection according to the table below.

[0116] Components quantity Specification Test strips 50 bags 1 piece / bag Sample buffer 1 tube 10mL / tube manual 1 serving /

[0117] ⑧Usage and judgment of test strips

[0118] 1. Sample processing

[0119] 1.1 Tissue sample processing method: The tissue sample was ground with PBS in a 1:1 ratio and then centrifuged to obtain the supernatant for direct detection.

[0120] 1.2 Blood test sample processing method: directly used for testing.

[0121] 2 Operation steps: Take an appropriate amount of test sample (30-40 μL, 1 drop with a dropper), slowly drip it into the sample well, and then add 2 drops of sample buffer. After adding the sample, place the test strip flat on the table and observe the results within 5-10 minutes.

[0122] 3. Determination (such as Fig.19 (shown)

[0123] 3.1 If two bands appear on the test strip (T: detection line, C: quality control line), it is judged as positive.

[0124] 3.2 If only one blue band (C: quality control line) appears on the test strip, it is judged as negative.

[0125] 3.3 If no band appears at the quality control line of the test strip, it will be judged as invalid.

[0126] (8) Product Application

[0127] ①Use the above-prepared product to treat PCV2 virus liquid (containing 10 6.0 TCID 50 / mL), PCV2 Cap protein, PEDV virus liquid (containing 10 7.0 TCID 50 / mL), PRV (including 10 8.0 TCID50 / mL) was tested, and the results showed that the test strip was negative, indicating that the test strip had good specificity.

[0128] ② The above-prepared product was used to detect PCV3 Cap protein of different concentrations. The results showed that the detection limit of the test strip for PCV3 Cap protein was 10,000 times dilution, at which time the concentration of PCV3 Cap protein was 80 ng / mL, indicating that the test strip had good sensitivity.

[0129] ③ Testing of clinical samples: A farm collected clinical blood samples from 14 pigs and tested them using the porcine circovirus type 3 antigen test strips (latex method) developed above according to the product instructions. The test results are as follows: Fig. 20 As shown in the figure, it can be seen that sample No. 4 among the 14 clinical serum samples showed a positive band (T line), which was consistent with the real-time quantitative PCR result, indicating that it was positive for porcine circovirus type 3 antigen.

[0130] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.

Claims

1. An anti-Porcine circovirus type 3 Cap protein monoclonal antibody, characterized in that: The anti-PCV3Cap protein monoclonal antibodies are monoclonal antibody 1D4-10-16 and monoclonal antibody 2B6-1-1, wherein the amino acid sequences of the heavy chain variable region and the light chain variable region of the monoclonal antibody 1D4-10-16 are shown in SEQ ID NO.3 and SEQ ID NO.4, respectively.

2. A porcine circovirus type 3 antigen detection test strip, characterized in that: The test strip includes a test strip and a matching sample diluent, wherein the test strip includes a PVC base plate, on which a sample pad, a latex microsphere pad, a nitrocellulose membrane and absorbent paper are fixed in sequence; the latex microsphere pad is a latex microsphere marked with an effective amount of a PCV3 Cap protein polyclonal antibody; a detection line and a quality control line are drawn on the surface of the nitrocellulose membrane, wherein the detection line is an effective amount of the monoclonal antibody 1D4-10-16 described in claim 1, and the quality control line is an effective amount of the PCV3 Cap protein.

3. The test strip according to claim 2, characterized in that: The concentration of the PCV3Cap protein polyclonal antibody on the latex microsphere pad when labeling the latex microspheres is 1 mg / mL.

4. The test strip according to claim 2, characterized in that: The PCV3 Cap protein polyclonal antibody is a rabbit anti-PCV3 Cap protein polyclonal antibody, and its ELISA titer is 1:80000.

5. The test strip according to claim 2, characterized in that: The concentration of monoclonal antibody 1D4-10-16 on the test line was 1 mg / mL.

6. The test strip according to claim 2, characterized in that: The concentration of PCV3 Cap protein on the test line is 1 mg / mL.

7. The test strip according to claim 2, characterized in that: The amino acid sequence of the PCV3 Cap protein is shown in SEQ ID NO.

1.

8. The test strip according to claim 2, characterized in that: The nucleotide sequence of the codon-optimized PCV3Cap protein is shown in SEQ ID NO.

2.

9. Use of the monoclonal antibody 1D4-10-16 as claimed in claim 1 in preparing a PCV3 or PCV3Cap protein detection reagent.

Citation Information

Patent Citations

  • PCV3 Cap protein epitope peptide, anti-PCV3 Cap protein monoclonal antibody, and preparation method and application thereof

    CN112812178A

  • Latex immunochromatography test strip for rapidly detecting swine transmissible gastroenteritis coronavirus and preparation method of latex immunochromatography test strip

    CN116699130A

  • Porcine circovirus type 3 (PCV3) vaccines, and production and uses thereof

    WO2020206452A1